Here, in a series of 48 breast cancer patients with HER2 gene amplification we retrospectively investigated numerous additional biomolecular parameters to have potential impact on the course of disease under HerceptinTM treatment (prognostic value) and to be implicated in responsiveness to HerceptinTM treatment (predictive value). The gene discussed is ERBB2; the disease is breast cancer.